UNSPSC 51413103: Flosequinan

This classification denotes a vasodilating agent with the molecular formula C11H10FNO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6NB119DLU7, chemically known as 4(1h)-quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)- but generally known as flosequinan, which bears US NIH Compound Identifier 53516. European Medicines Agency schedules Flosequinan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07654MIG.

UNSPSC 51413103 Flosequinan, a Commodity code, covers cardiac and emergency pharmaceutical products supplied to state and local health-care and emergency-response agencies. State and local governments procure these medications directly for emergency medical services, hospital formularies, and public health programs. Recent solicitations show city fire departments and state health agencies acquiring specific emergency medications including epinephrine, adenosine, diltiazem, and labetalol through competitive bids and cooperative purchasing agreements. The buying mix spans city purchasing departments managing fire-rescue operations, state health agencies coordinating pharmacy benefit programs, and multistate cooperative purchasing alliances aggregating demand across jurisdictions. Work under this code includes sealed-bid procurement of branded and generic pharmaceuticals with strict expiration and shelf-life requirements, competitive RFP processes for multi-state generic drug supply agreements, and information-gathering phases to reshape pharmacy benefit delivery models around direct manufacturer relationships.

Geographic activity centers on Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026) for use by Tampa Fire Rescue, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a firm-price IFB valued at $40,000 and a one-year contract term with renewal options. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013, due April 3, 2026) to assess vendor capability for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with a two-year contract term and awards effective July 1, 2026. Small and local business enterprise set-asides appear in city-level procurements; no set-asides are identified in state or cooperative purchasing opportunities reviewed.